Jill J.J. Geenen

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

Udai Banerji, Carla M.L. van Herpen, Cristina Saura et al. · The Lancet Oncology · 2019 · 549 citations · Full text

Breast Oncology, Her2-expressing Breast Cancer, Medicine +9

Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer

Jill J.J. Geenen, Jan H.M. Schellens · Clinical Cancer Research · 2017 · 143 citations · Full text

A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer.

Cristina Saura, Fiona Thistlethwaite, Udai Banerji et al. · Journal of Clinical Oncology · 2018 · 63 citations

Breast Oncology, Pathology, Tumor Biology +16

WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study

Alaa Embaby, Joachim Kutzera, Jill J.J. Geenen et al. · Gynecologic Oncology · 2023 · 39 citations · Full text

Medicine, Advanced Tp53, Cell Biology +8

Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study.

Kathleen N. Moore, Setsuko K. Chambers, Erika Hamilton et al. · Journal of Clinical Oncology · 2019 · 22 citations

Cancer Management, Gynecology, Phase Ii Study +19